Oral Gene Delivery: An Innovative Approach for Colorectal Center Therapy
Colorectal cancer is the third most commonly diagnosed cancer in the world characterized by neoplasia in the colon, rectum, or vermiform appendix. Current treatment approaches include chemotherapy, radiotherapy and surgery however non-specific bio-distribution of anti-cancer drug, lack of effective and safe drug delivery career, drug resistance and relapse are major limiting factors of current therapy. Gene therapy is a technique for correcting defective genes responsible for disease development. The future of gene therapy depends on achieving successful delivery of wild type gene to replace a faulty gene. Recently, there has been an increasing interest in delivery of drugs and gene via the gastrointestinal tract. Gene therapy via this route has many advantages, including non-invasive access and the versatility to treat local diseases, such as inflammatory bowel disease, colorectal cancer, as well as systemic diseases, such as haemophilia. However, the intestine presents several distinct barriers and, therefore, the design of robust non-viral delivery systems is key to future success. The review covers obstacles in the path of successful gene therapy using oral route to treat colorectal cancer as well as strategies to overcome.
Keywords: Colorectal cancer, Oral gene delivery, Targeted delivery
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
3. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro</em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.
4. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. European journal of cancer (Oxford, England : 1990). 1999;35(3):335-51.
5. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA: a cancer journal for clinicians. 2004;54(6):295-308.
6. Sancho E, Batlle E, Clevers H. SIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER. Annual Review of Cell and Developmental Biology. 2004;20(1):695-723.
7. Pinto D, Clevers H. Wnt, stem cells and cancer in the intestine. Biology of the cell. 2005;97(3):185-96.
8. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016;226:148-67.
9. Strate LL, Syngal S. Hereditary colorectal cancer syndromes. Cancer causes & control : CCC. 2005;16(3):201-13.
10. Croce CM. Oncogenes and Cancer. New England Journal of Medicine. 2008;358(5):502-11.
11. Kaler P, Galea V, Augenlicht L, Klampfer L. Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells. PloS one. 2010; 5(7):e11700.
12. Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer Research. 2016; 76(14 Supplement):2063.
13. Astin M, Griffin T, Neal RD, Rose P, Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. The British journal of general practice : the journal of the Royal College of General Practitioners. 2011; 61(586):e231-43.
14. Fearon ER. Molecular genetics of colorectal cancer. Annual review of pathology. 2011; 6:479-507.
15. Hemal Tandel PB, Keerti Jain, Aliasgar Shahiwala, Ambikanandan Misra. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASaA, editor. In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes: CRC Press; 2018.
16. Chen MJ, Cheng YM, Lai PH, Wu JF, Hsu YC. In vitro biocompatibility of thermally gelling liquid mucoadhesive loaded curcuminoids in colorectal cancer chemoprevention. International journal of colorectal disease. 2012; 27(7):869-78.
17. Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2013; 191:157-83.
18. Javia A, Amrutiya J, Lalani R, Patel V, Bhatt P, Misra A. Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. Ther Deliv. 2018; 9(5):375-86.
19. Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw JJ, Chen B, et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Critical reviews in oncology/hematology. 2013; 86(3):232-50.
20. Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World journal of gastroenterology. 2015; 21(41):11767-76.
21. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
22. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6):394-424.
23. Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS, Chakraborty C. Advances in nanocarriers enabled brain targeted drug delivery across blood brain barrier. International journal of pharmaceutics. 2019; 559:360-72.
24. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018; 35(2):204-17.
25. Silva CO, Pinho JO. Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems. 2019; 11(1).
26. Ehrlich P, Himmelweit F. The collected papers of Paul Ehrlich : in four volumes, including a complete bibliography. London; New York: Pergamon Press; 1956.
27. Hansch C, Leo A, Hoekman D, editors. Exploring QSAR: Hydrophobic, electronic, and steric constants. Washington, DC: American Chemical Society; 1995.
28. Martin YC. Exploring QSAR: Hydrophobic, Electronic, and Steric Constants C. Hansch, A. Leo, and D. Hoekman. American Chemical Society, Washington, DC. 1995. Xix + 348 pp. 22 × 28.5 cm. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology. C. Hansch and A. Leo. American Chemical Society, Washington, DC. 1995. Xvii + 557 pp. 18.5 × 26 cm. ISBN 0-8412-2993-7 (set). $99.95 (set). Journal of Medicinal Chemistry. 1996; 39(5):1189-90.
29. Bhatt P, Fnu G, Bhatia D, Shahid A, Sutariya V. Nanodelivery of Resveratrol-Loaded PLGA Nanoparticles for Age-Related Macular Degeneration. AAPS PharmSciTech. 2020; 21(8):291.
30. Dhanikula AB, Panchagnula R. Localized paclitaxel delivery. International journal of pharmaceutics. 1999; 183(2):85-100.
31. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003; 4(3):E33-E.
32. Achim M, Tomuta I, Vlase L, Iuga C, Moldovan M, Leucuta SE. Paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres: preparation and in vitro evaluation. Journal of Drug Delivery Science and Technology. 2008; 18(6):410-6.
33. Manish G, Vimukta S, editors. Targeted drug delivery system: A Review2011.
34. Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and In Vitro Characterization. ASSAY and Drug Development Technologies. 2019; 17(4):167-77.
35. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. Journal of controlled release : official journal of the Controlled Release Society. 2017; 264:306-32.
36. Vhora I, Lalani R, Bhatt P, Patil S, Patel H, Patel V, et al. Colloidally Stable Small Unilamellar Stearyl Amine Lipoplexes for Effective BMP-9 Gene Delivery to Stem Cells for Osteogenic Differentiation. AAPS PharmSciTech 2018; 19:3550–60.
37. Raucher D, Dragojevic S, Ryu J. Macromolecular Drug Carriers for Targeted Glioblastoma Therapy: Preclinical Studies, Challenges, and Future Perspectives. Frontiers in oncology. 2018; 8:624.
38. Goel A, Baboota S, Sahni JK, Ali J. Exploring targeted pulmonary delivery for treatment of lung cancer. Int J Pharm Investig. 2013;3(1):8-14.
39. Ding J, Feng M, Wang F, Wang H, Guan W. Targeting effect of PEGylated liposomes modiﬁed with the Arg-Gly-Asp sequence on gastric cancer. Oncology reports. 2015; 34(4):1825-34.
40. Patil S, Lalani R, Bhatt P, Vhora I, Patel V, Patel H, et al. Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances. 2018; 8(62):35461-73.
41. Xie J, Xiao D, Zhao J, Hu N, Bao Q, Jiang L, et al. Mesoporous Silica Particles as a Multifunctional Delivery System for Pain Relief in Experimental Neuropathy. Adv Healthc Mater. 2016; 5(10):1213-21.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).